FAT1 Enhances the Sensitivity of Non‐Small Cell Lung Cancer to VCP Inhibitors by Regulating the Activation of the Endoplasmic Reticulum Stress Pathway
The FASEB Journal · 15.05.2025 · 39 (9)
DOI: 10.1096/fj.202500097rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 28.04.2025. Verfasst von Xiangning Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Valosin Containing Protein, Endoplasmic Reticulum Stress, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Natural Science Foundation of China.
Abstract (Originalsprache)
FAT atypical cadherin 1 (FAT1) is prevalently expressed in non‐small cell lung cancer (NSCLC) tissues and is associated with poor prognosis in patients. Using data from the PRISM Repurposing drug sensitivity database, we observed that among compounds related to protein homeostasis, the valosin‐containing protein (VCP) inhibitor CB‐5083 demonstrated the most significant variation in sensitivity among NSCLC cells, categorized according to FAT1 expression levels. Notably, CB‐5083 markedly inhibits cell proliferation and induces apoptosis in NSCLC cells with high expression of FAT1 . Targeting VCP may trigger strong endoplasmic reticulum stress (ER stress) in NSCLC cells, leading to inhibition of cell proliferation in tumor cells. Mechanically, knockdown of FAT1 stimulates YAP signaling and target gene transcription, thereby attenuating the UPR pathway signal induced by CB‐5083 stimulation in NSCLC cells. Our results suggest that FAT1 regulates the activation of the ER stress pathway through YAP signaling, influencing the susceptibility of NSCLC cells to VCP inhibitors. These insights provide novel perspectives for NSCLC treatment and extend the therapeutic applications of VCP inhibitors in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
- School of Medicine, Hangzhou City University, Hangzhou, China.
- The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Fangjie Yan
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Natural Science Foundation of China
Zitieren
APA
Liu, X., Zhang, P., Ge, F., Yuan, T., Guo, R., Yang, S., Yang, B., Zhu, H., Yan, F., & He, Q. (2025). FAT1 Enhances the Sensitivity of Non‐Small Cell Lung Cancer to VCP Inhibitors by Regulating the Activation of the Endoplasmic Reticulum Stress Pathway. The FASEB Journal, 39(9). https://doi.org/10.1096/fj.202500097rr
Vancouver
Liu X, Zhang P, Ge F, Yuan T, Guo R, Yang S, et al. FAT1 Enhances the Sensitivity of Non‐Small Cell Lung Cancer to VCP Inhibitors by Regulating the Activation of the Endoplasmic Reticulum Stress Pathway. The FASEB Journal. 2025;39(9). doi:10.1096/fj.202500097rr
BibTeX
@article{Liu2025,
author = {Liu, Xiangning and Zhang, Peiying and Ge, Fujing and Yuan, Tao and Guo, Runqiu and Yang, Shuyu and Yang, Bo and Zhu, Hong and Yan, Fangjie and He, Qiaojun},
title = {FAT1 Enhances the Sensitivity of Non‐Small Cell Lung Cancer to VCP Inhibitors by Regulating the Activation of the Endoplasmic Reticulum Stress Pathway},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {9},
doi = {10.1096/fj.202500097rr}
}
EUVIMED